Preview

Acct 712

Better Essays
Open Document
Open Document
643 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Acct 712
Ques 1:
Considering the facts given in this case, I would argue that ASC 470-10 is not applicable in this situation. Product “X” is undeveloped and the status is undetermined, therefore, payments are not guaranteed through the future revenues of this particular product (ASC 470-10-25-1). Further, based on ASC 470-10-25-2, these factors do not apply in this case to qualify as a debt.
However, the facts below would show why it is more appropriate to account for the financing of the research and development for product “X”, under ASC 730-20:

1. The main reason behind PEI investment in providing funding for the research and development for product “X”, is to purchase the rights to receive future royalties from Pharmagen, even if product “X” is not successfully completed and developed. Further, based ASC 730-20-05-3 through 6, Pharmagen has incurred a liability, and has promised to repay this loan using future revenues from either or both product “X” and “Y”, regardless of the outcome of product “X”. There are also no financial risks transferred over to PEI, as they would be paid no matter what the result of product “X”.

2. Another factor is that Pharmagen is also partially financing the research and development for product “X”. Plus, they had already started the research and development process prior to the contract agreement, and therefore, the success or failure of this product can have a great impact on this Pharmagen.

3. They have also retained all intellectual property rights to product “X. And once Pharmagen continues to perform its duties on a “best effort” basis, in the research and development process of product “X”, they will continue to receive financing from PEI, without having the obligation to complete the product. Moreover, this proves that Pharmagen is not fulfilling a contract to perform services to PEI, but is working on a project, which can bring future economic benefits to its company (ASC 730-20-05-4).

Ques 2:
ASC

You May Also Find These Documents Helpful

  • Satisfactory Essays

    Trueblood Case 09 2

    • 804 Words
    • 2 Pages

    Position: I believe it is obvious that this agreement is applicable to the treatment of ASC 730-20 as a research and development arrangement based on ASC 730-20-20’s definitions. It now becomes important to determine the nature of the obligation and distinguish if the funding is a liability to repay the PEI or an obligation to perform contractual services. According to ASC 730-20-25-4, “To conclude that a liability does not exist, the transfer of the financial risk involved with research and development from the entity to the other parties must be substantive and genuine.” You can then look to ASC 730-20-25-6 for the four conditions that will lead to the presumption that the entity will repay the other party. If any of these conditions are met, the funding would create a liability. The fact that Pharmagen has no indent to repay the…

    • 804 Words
    • 2 Pages
    Satisfactory Essays
  • Good Essays

    Acct 305

    • 1105 Words
    • 5 Pages

    Alpha Company's stock trades on the NY stock exchange. For Alpha Company, revenue on account amounted to $5,150. Cash collections of accounts receivable amounted to $2,300. Expenses incurred on account were $2,100. Cash paid on accounts payable was $1,950. Alpha's net income was…

    • 1105 Words
    • 5 Pages
    Good Essays
  • Powerful Essays

    Direct Drugs Inc. (Direct) has created a plan for the acquisition of SolvGen Inc. (SolvGen), which is a publicly owned company. Direct has engaged an audit team to review agreement and procedures dealing with two separate material agreements. The first agreement is a research and development agreement and the second is a licensing and distribution agreement. The contract states that SolvGen entered into a five year research and development agreement with Careway Pharma Inc. on January 1, 2010. The agreement states that SolvGen will use its best efforts to develop a proprietary instrument system. They are expected to be ready for launch in the near future. SolvGen and Careway also entered in an agreement for a five year license and distribution. This agreement was entered in on January 1, 2010 as well. The terms of the research and development agreement state that SolvGen holds all intellectual rights that correspond with the research and development of the contract. Also with this agreement SolvGen is entitled to nonrefundable milestone payments from Careway and they are as follows:…

    • 1100 Words
    • 5 Pages
    Powerful Essays
  • Good Essays

    Pharmagen

    • 508 Words
    • 2 Pages

    1. Since there is no obligation to the nonrefundable repayment of the $500 million of funding and Pharma retains intellectual rights (no financial risk for Pharma as per ASC 730-20-25-4), it can be seen as a Research and Development and expensed as incurred according to ASC 730-20-35-1 because no future service can be made. The funding for product X is specified by the investor to be used only for R&D of product X which is not commercialized and not for a future project. The royalties that come from product X are not for a defined period. Product Y is for a defined period. In both cases, both aren’t measured as to how much royalties will be received and whether it can be estimated. Unless there is royalties, the investor gets nothing Since royalties aren’t measurable and are obligations only if product is developed and entity actually receives it, R&D are expensed as incurred for product X as R&D. Incremental funding has the same appearance to be expensed because no future obligation is required.…

    • 508 Words
    • 2 Pages
    Good Essays
  • Satisfactory Essays

    acct 553

    • 364 Words
    • 2 Pages

    According to the IRS Audit Techniques Guide there is not a specific hour requirement. Even if you use a management company, you will be considered active if you are involved with the operation of your rental. However, the taxpayer must be exercising independent judgment and not simply ratifying decisions made by a manager or management company. In addition, the taxpayer must have at least a 10% interest in the rental activity.…

    • 364 Words
    • 2 Pages
    Satisfactory Essays
  • Powerful Essays

    While the Patent Act is a general act in the sense that it covers all inventions, it does have sections that relate specifically to the pharmaceutical sector. There are 4 important aspects that fully describe the rights and issues related to pharmaceutical patents : (1) the criteria that qualifies a drug for patent consideration, (2) the right of exclusive commercialization which is the most important right granted to the patent holder (3) Health Canada’s regulatory process for safely introducing a drug into the marketplace, known as the Notice of Compliance (NOC) Regulations and finally (4) the Patented Medicine Prices Review Board (PMPRB), a quasi-judicial body whose role is to ensure reasonable pricing of protected drugs. Each aspect…

    • 9240 Words
    • 37 Pages
    Powerful Essays
  • Satisfactory Essays

    Crazy Computers

    • 454 Words
    • 2 Pages

    This case discusses the company Direct Drugs Inc. and their plans to acquire SolvGen Inc. SolvGen Inc. has two material agreements with Careway Pharma Inc. One of the case requirements asks what the deliverables for the arrangement described in the case study were. These being the research and development agreement and a license and distribution agreement. The next requirement asked when the milestone payments received to date by SolvGen were to be recognized as revenue. The nonrefundable milestones include an exclusive negotiation payment of $1 million dollars paid on December 1, 2009, contract signing payment of $2 million paid on January 1, 2010, a commercial…

    • 454 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    - Profits from future sales of drugs in North America and Europe would be split 50/50…

    • 771 Words
    • 4 Pages
    Satisfactory Essays
  • Better Essays

    Leading Pharmaceutical companies have, in recent times, been alarmed by the some adverse regulatory rulings in India. First in a landmark decision in March 2012, the Indian Patent Office allowed a domestic company (Natco Pharma Ltd.) to sell a generic version of Bayer AG's cancer drug ‘Nexavar’ on the grounds that the German company’s drug not affordable to the local populace due to cost reasons. Then in March 2013, the Honorable Supreme Court of India denied patent protection to Novartis’s blockbuster cancer drug ‘Gleevac’ stating that Novartis had resorted to ‘evergreening’ in an effort to extend their monopoly beyond the standard patent period. The Indian ruling has attracted global attention especially from the Big Pharma companies here in the U.S. The view is that India has scant disregard of intellectual property (IP) and pharmaceutical patent polices and the rulings are geared to favor local generic drug makers by way of issuing compulsory licenses. Pfizer’s Chief IP counsel Roy F. Waldron had, in written testimony before the US House Committee hearing on US-India trade relations in March 2013, accused India of being anti-IP rights. In his testimony he mentions that the “Business environment (in India) for innovative industries has deteriorated significantly in recent history” and “India has taken steps that call into question the sustainability of foreign investment and the ability of American companies to compete fairly.”…

    • 1572 Words
    • 7 Pages
    Better Essays
  • Satisfactory Essays

    Vertex Case Team 2

    • 543 Words
    • 6 Pages

    probability, pralnacasan deal with Aventis, oral not injection, good antiinflammatory drug has high potential, relatively quick to market (2008),…

    • 543 Words
    • 6 Pages
    Satisfactory Essays
  • Good Essays

    Ecton Case Analysis

    • 638 Words
    • 2 Pages

    3. Another important consideration is that the product has not been tested commercially till date. Though the product has a significant advantage in the target market but the real test for the product begins when it is commercially launched in the market. Even research companies have not given any major encouragement and in this case it may prove difficult to find the right buyer and then convincing the buyer of the right price for acquisition would prove to be another uphill task.…

    • 638 Words
    • 2 Pages
    Good Essays
  • Good Essays

    Anacomp

    • 621 Words
    • 3 Pages

    Anacomp would develop the CIS system on behalf of the partnership. In return, the four banks collectively contributed $6 million and 24 software development people for 2 years to the project. The same considerations were present in each of the four subsequent partnerships. Each partnership assumed development risks; except for BANKSERV 10000. Any product developed becomes the property of the partnership. Upon completion of the development of the CIS system, Anacomp agreed to market CIS for 5 years on a commission basis. Anacomp also had the option to acquire all rights to the CIS system at the greater of its appraised fair market value or RTS’s investment plus a fixed profit but is under no obligation to exercise this option. RTS had the right to extend Anacomp’s 5-year marketing agreement an additional 5 year or to cancel it if Anacomp did not use its best efforts to market CIS. If the CIS development expenses exceed $6 million, the RTS was required to pay further development fees, Anacomp agreed to loan RTS, without recours…

    • 621 Words
    • 3 Pages
    Good Essays
  • Good Essays

    Alza Corp Case Study

    • 984 Words
    • 4 Pages

    ALZA, a pharmaceutical company that has led the industry for over a decade, has been largely successful due to their unique technical innovation. Rather than specializing in discovering new drugs and treatments for medical conditions, ALZA instead focuses their pharmaceutical talents on developing new methods to deliver drugs to patients. From skin patches to time released capsules, ALZA captures their market by providing their technologies to all major pharmaceutical companies, in return charging royalties that has led the company to realize immense consecutive profits. However, drug delivery technologies are constantly evolving, which has caused more effective and efficient methods to appear at a rapid rate. While ALZA is a leader in its industry, it needs to invest in advancing their own technologies if it wants to enjoy its current state of profitability, growth, and leadership. To implement this effort of advancing its drug delivery technologies, Martin Gerstel, CEO of ALZA, approved a 40 million dollar proposal to aid in developing its technologies. Yet, the solution wasn't nearly as simple as they had hoped, the company still needed to develop a method of organizing and paying for the 40 million dollar project. The company came up with three options:…

    • 984 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    Tradition and Technology

    • 3666 Words
    • 15 Pages

    Dailey, Melissa and McFalrlan, Warren F. “Providian Trust: Tradition and Technology (A)”, Harvard Business School, June 7, 1997.…

    • 3666 Words
    • 15 Pages
    Powerful Essays
  • Powerful Essays

    pharmaceutical innovations1. It provides the innovators 20 years of royalty to recover their investments done in research and development of the…

    • 1493 Words
    • 6 Pages
    Powerful Essays

Related Topics